Page last updated: 2024-12-07

ici 200355

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ICI 200355: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122024
MeSH IDM0189355

Synonyms (12)

Synonym
ici 200355
4-(4-bromophenylsulfonylcarbamoyl)benzoyl-l-valyl-l-proline-1(rs)-(1-trifluoroacetyl-2-methylprolyl)amide
l-prolinamide, n-(4-((((4-bromophenyl)sulfonyl)amino)carbonyl)benzoyl)-l-valyl-n-(3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl)-
ici-200,355
4-n-(4-bromophenyl)sulfonyl-1-n-[(2s)-3-methyl-1-oxo-1-[(2s)-2-[(1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)carbamoyl]pyrrolidin-1-yl]butan-2-yl]benzene-1,4-dicarboxamide
105080-32-8
ccris 8142
n1-((4-bromophenyl)sulfonyl)-n4-((2s)-3-methyl-1-oxo-1-((2s)-2-((1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)carbamoyl)pyrrolidin-1-yl)butan-2-yl)terephthalamide
uuwiyanokphuqz-otkihzfjsa-n
1-(n-{4-[(4-bromobenzene-1-sulfonyl)carbamoyl]benzoyl}valyl)-n-(1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)pyrrolidine-2-carboximidic acid
DTXSID70909319
AKOS040746914

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Two of these compounds, 1k and 1l, have high levels of oral bioavailability in several species."( Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
Bernstein, PR; Bohnert, CM; Brown, FJ; Bryant, C; Damewood, JR; Earley, R; Edwards, PD; Feeney, SW; Gomes, B; Hulsizer, JM; Kosmider, BJ; Krell, RD; Moore, G; Salcedo, TW; Shaw, A; Silberstein, DS; Steelman, GB; Stein, M; Strimpler, A; Thomas, RM; Vacek, EP; Veale, CA; Williams, JC; Wolanin, DJ; Woolson, S, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Subcutaneous administration of either 50 or 100 mumol/kg (twice/day) of ICI 200,880 for 14 or 28 days prevented the time-dependent increase in alveolar diameter produced by a single intratracheal dose of PPE when compound dosing was initiated 24 h after the enzyme."( Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase.
Falcone, RC; Giles, RE; Knee, C; Krell, RD; Reaves, B; Stein, RL; Strimpler, AM; Williams, JC, 1991
)
0.28
" At a 30 min prechallenge interval, compound 9, which incorporates this substituent, had an ED50 of approximately 2 nmol/animal and, qualitatively, afforded a very similar dose-response relationship to that found with a peptidic trifluoromethyl ketone inhibitor, ICI 200,355."( Nonpeptidic inhibitors of human leukocyte elastase. 6. Design of a potent, intratracheally active, pyridone-based trifluoromethyl ketone.
Bernstein, PR; Gomes, BC; Kosmider, BJ; Vacek, EP; Williams, JC, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's19 (95.00)18.2507
2000's1 (5.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.36 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]